ISK

Serial Number 79186613
Registration 5173581
706

Registration Progress

Application Filed
Feb 2, 2016
Under Examination
Approved for Publication
Dec 28, 2016
Published for Opposition
Jan 17, 2017
Registered
Apr 4, 2017

Trademark Image

ISK

Basic Information

Serial Number
79186613
Registration Number
5173581
Filing Date
February 2, 2016
Registration Date
April 4, 2017
Published for Opposition
January 17, 2017
Drawing Code
3

Status Summary

Current Status
Active
Status Code
706
Status Date
Mar 22, 2024
Registration
Registered
Classes
005

Rights Holder

ISHIHARA SANGYO KAISHA, LTD.

03
Address
3-15, Edobori, 1-Chome
Nishi-Ku, Osaka-Shi
Osaka 550-0002
JP

Ownership History

ISHIHARA SANGYO KAISHA, LTD.

Original Applicant
03
Osaka JP

ISHIHARA SANGYO KAISHA, LTD.

Owner at Publication
03
Osaka 550-0002 JP

ISHIHARA SANGYO KAISHA, LTD.

Original Registrant
03
Osaka 550-0002 JP

Legal Representation

Attorney
Joseph S. Presta

USPTO Deadlines

Next Deadline
611 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2017-04-04)
Due Date
April 04, 2027
Grace Period Ends
October 04, 2027

Application History

40 events
Date Code Type Description Documents
Nov 23, 2024 INPR P PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED Loading...
Oct 18, 2024 INNP P PARTIAL INVALIDATION PROCESSED BY THE IB Loading...
Jul 23, 2024 INPC P INVALIDATION PROCESSED Loading...
Jul 23, 2024 INPS P PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB Loading...
Jun 14, 2024 INPR P PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED Loading...
Mar 22, 2024 NA71 E NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED Loading...
Mar 22, 2024 71AG O REGISTERED-SEC.71 ACCEPTED Loading...
Feb 22, 2024 EROP I TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED Loading...
Oct 10, 2023 PR71 O POST REGISTRATION ACTION MAILED - SEC.71 Loading...
Oct 5, 2023 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Mar 15, 2023 ES71 I TEAS SECTION 71 RECEIVED Loading...
Jun 17, 2022 RNWL P INTERNATIONAL REGISTRATION RENEWED Loading...
Apr 4, 2022 REM3 E COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Loading...
Aug 4, 2017 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Jul 14, 2017 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Jul 14, 2017 FIMP P FINAL DISPOSITION PROCESSED Loading...
Jul 4, 2017 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Apr 4, 2017 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Mar 16, 2017 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jan 17, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 12, 2017 GPNX P NOTIFICATION PROCESSED BY IB Loading...
Dec 28, 2016 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Dec 28, 2016 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
Dec 28, 2016 NPUB O NOTICE OF PUBLICATION Loading...
Dec 15, 2016 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Dec 10, 2016 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 10, 2016 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 10, 2016 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 7, 2016 ALIE A ASSIGNED TO LIE Loading...
Nov 18, 2016 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 10, 2016 RFNT P REFUSAL PROCESSED BY IB Loading...
May 23, 2016 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
May 23, 2016 RFRR P REFUSAL PROCESSED BY MPU Loading...
May 21, 2016 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
May 20, 2016 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 15, 2016 DOCK D ASSIGNED TO EXAMINER Loading...
May 14, 2016 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
May 10, 2016 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 9, 2016 LIMI I LIMITATION FROM ORIGINAL APPLICATION ENTERED Loading...
May 5, 2016 SDRC M SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of Anti-inflammatory, [ anti-shock, ] inflammation of digestive system, [ inflammation of respiratory system, ] anti-pancreatitis, [ pulmonary insufficiency, kidney disease, disseminated intravascular coagulation, chronic obstructive pulmonary disease, pyometra, spondylosis deformans, systemic inflammatory response syndrome, pneumonia, infectious peritonitis, sepsis, inhibiting thrombogenesis, allergy, tumor metastasis control, infectious disease, encephalitis and surgical stress; ] veterinary preparations for Companion animals, farm animals, dogs [, cats, horses, chickens, cattle and pigs ] for the treatment of Anti-inflammatory, [ anti-shock, ] inflammation of digestive system, [ inflammation of respiratory system, ] anti-pancreatitis, [ pulmonary insufficiency, kidney disease, disseminated intravascular coagulation, chronic obstructive pulmonary disease, pyometra, spondylosis deformans, systemic inflammatory response syndrome, pneumonia, infectious peritonitis, sepsis, inhibiting thrombogenesis, allergy, tumor metastasis control, infectious disease, encephalitis and surgical stress; ] pharameutical agents affecting digestive organs; [ pharmaceutical preparations for skin care for animals; pharmaceutical preparations and ] agents, namely, medical test kits composed primarily of reagents and vectors; veterinary preparations and agents, namely, medical test kits composed primarily of reagents and vectors; pharmaceutical preparations and agents, namely, surgical or orthopedic bone cement and medical bone bonding agent; [ veterinary preparations and agents, namely, surgical or orthopedic bone cement and medical bone bonding agent; ] medicines for veterinary purposes for Companion animals, farm animals, dogs [, cats, horses, chickens, cattle and pigs ] for the treatment of Anti-inflammatory, [ anti-shock, ] inflammation of digestive system, [ inflammation of respiratory system, ] anti-pancreatitis [, pulmonary insufficiency, kidney disease, disseminated intravascular coagulation, chronic obstructive pulmonary disease, pyometra, spondylosis deformans, systemic inflammatory response syndrome, pneumonia, infectious peritonitis, sepsis, inhibiting thrombogenesis, allergy, tumor metastasis control, infectious disease, encephalitis and surgical stress ]

Additional Information

Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
ISHIHARA SANGYO KAISHA

Classification

International Classes
005